NCT04728347View on ClinicalTrials.gov

Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

PHASE2TerminatedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

December 28, 2021

Study Completion Date

December 28, 2021

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

ARCT-021

ARCT-021 single dose

Trial Locations (1)

169608

SingHealth Investigational Medicine Unit (IMU), Singapore General Hospital, Singapore

Sponsors
All Listed Sponsors
lead

Arcturus Therapeutics, Inc.

INDUSTRY

NCT04728347 - Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021 | Biotech Hunter | Biotech Hunter